Bortezomib-Induced Reticular Eruption in Patient with Multiple Myeloma
Bortezomib is the first proteasome inhibitor to treat a variety of malignancies and is currently part of the standard of care regimen for the initial treatment of patients with newly diagnosed multiple myeloma. While bortezomib is generally well tolerated, it has been associated with various side ef...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-07-01
|
| Series: | Dermatopathology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2296-3529/10/3/31 |
| _version_ | 1797580620743835648 |
|---|---|
| author | Joseph Han Shayan Owji Aneesh Agarwal Samir Kamat Yen Luu Adnan Mubasher George Niedt Chloe Ray Hearn Jay Cho Nicholas Gulati Angela Lamb |
| author_facet | Joseph Han Shayan Owji Aneesh Agarwal Samir Kamat Yen Luu Adnan Mubasher George Niedt Chloe Ray Hearn Jay Cho Nicholas Gulati Angela Lamb |
| author_sort | Joseph Han |
| collection | DOAJ |
| description | Bortezomib is the first proteasome inhibitor to treat a variety of malignancies and is currently part of the standard of care regimen for the initial treatment of patients with newly diagnosed multiple myeloma. While bortezomib is generally well tolerated, it has been associated with various side effects, which have limited its use in some patients. Here, we describe a unique case with histological confirmation of a reticular eruption that appeared at the site of a subcutaneous administration of bortezomib in a 62-year-old male who was newly diagnosed with IgG kappa multiple myeloma. A skin biopsy was performed, which revealed superficial perivascular dermatitis predominantly composed of lymphocytes with rare eosinophils. The patient was successfully treated with betamethasone dipropionate 0.05% cream. When consulted, dermatologists should advise the oncology team of multiple myeloma patients treated with bortezomib to maintain a high threshold before discontinuing the drug when a patient experiences an atypical, reticular rash following subcutaneous administration. Additionally, potent topical corticosteroids, such as betamethasone dipropionate 0.05% cream, should be considered in managing the cutaneous reticular eruptions related to bortezomib administration, in order to maintain an optimal treatment regimen for patients with multiple myeloma. |
| first_indexed | 2024-03-10T22:53:26Z |
| format | Article |
| id | doaj.art-9dffb2d0ed9c40bab6a55d4f4000b2f9 |
| institution | Directory Open Access Journal |
| issn | 2296-3529 |
| language | English |
| last_indexed | 2024-03-10T22:53:26Z |
| publishDate | 2023-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Dermatopathology |
| spelling | doaj.art-9dffb2d0ed9c40bab6a55d4f4000b2f92023-11-19T10:12:20ZengMDPI AGDermatopathology2296-35292023-07-0110322623010.3390/dermatopathology10030031Bortezomib-Induced Reticular Eruption in Patient with Multiple MyelomaJoseph Han0Shayan Owji1Aneesh Agarwal2Samir Kamat3Yen Luu4Adnan Mubasher5George Niedt6Chloe Ray7Hearn Jay Cho8Nicholas Gulati9Angela Lamb10Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USADepartment of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USADepartment of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USADepartment of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USASchool of Medicine, University of Missouri-Kansas City, Kansas City, MO 64108, USADepartment of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USADepartment of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USATisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USATisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USADepartment of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USADepartment of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USABortezomib is the first proteasome inhibitor to treat a variety of malignancies and is currently part of the standard of care regimen for the initial treatment of patients with newly diagnosed multiple myeloma. While bortezomib is generally well tolerated, it has been associated with various side effects, which have limited its use in some patients. Here, we describe a unique case with histological confirmation of a reticular eruption that appeared at the site of a subcutaneous administration of bortezomib in a 62-year-old male who was newly diagnosed with IgG kappa multiple myeloma. A skin biopsy was performed, which revealed superficial perivascular dermatitis predominantly composed of lymphocytes with rare eosinophils. The patient was successfully treated with betamethasone dipropionate 0.05% cream. When consulted, dermatologists should advise the oncology team of multiple myeloma patients treated with bortezomib to maintain a high threshold before discontinuing the drug when a patient experiences an atypical, reticular rash following subcutaneous administration. Additionally, potent topical corticosteroids, such as betamethasone dipropionate 0.05% cream, should be considered in managing the cutaneous reticular eruptions related to bortezomib administration, in order to maintain an optimal treatment regimen for patients with multiple myeloma.https://www.mdpi.com/2296-3529/10/3/31bortezomibcutaneous drug eruptionmultiple myelomareticular |
| spellingShingle | Joseph Han Shayan Owji Aneesh Agarwal Samir Kamat Yen Luu Adnan Mubasher George Niedt Chloe Ray Hearn Jay Cho Nicholas Gulati Angela Lamb Bortezomib-Induced Reticular Eruption in Patient with Multiple Myeloma Dermatopathology bortezomib cutaneous drug eruption multiple myeloma reticular |
| title | Bortezomib-Induced Reticular Eruption in Patient with Multiple Myeloma |
| title_full | Bortezomib-Induced Reticular Eruption in Patient with Multiple Myeloma |
| title_fullStr | Bortezomib-Induced Reticular Eruption in Patient with Multiple Myeloma |
| title_full_unstemmed | Bortezomib-Induced Reticular Eruption in Patient with Multiple Myeloma |
| title_short | Bortezomib-Induced Reticular Eruption in Patient with Multiple Myeloma |
| title_sort | bortezomib induced reticular eruption in patient with multiple myeloma |
| topic | bortezomib cutaneous drug eruption multiple myeloma reticular |
| url | https://www.mdpi.com/2296-3529/10/3/31 |
| work_keys_str_mv | AT josephhan bortezomibinducedreticulareruptioninpatientwithmultiplemyeloma AT shayanowji bortezomibinducedreticulareruptioninpatientwithmultiplemyeloma AT aneeshagarwal bortezomibinducedreticulareruptioninpatientwithmultiplemyeloma AT samirkamat bortezomibinducedreticulareruptioninpatientwithmultiplemyeloma AT yenluu bortezomibinducedreticulareruptioninpatientwithmultiplemyeloma AT adnanmubasher bortezomibinducedreticulareruptioninpatientwithmultiplemyeloma AT georgeniedt bortezomibinducedreticulareruptioninpatientwithmultiplemyeloma AT chloeray bortezomibinducedreticulareruptioninpatientwithmultiplemyeloma AT hearnjaycho bortezomibinducedreticulareruptioninpatientwithmultiplemyeloma AT nicholasgulati bortezomibinducedreticulareruptioninpatientwithmultiplemyeloma AT angelalamb bortezomibinducedreticulareruptioninpatientwithmultiplemyeloma |